Pricing Log in Create free account

Gyre Therapeutics, Inc. (GYRE) vs OmniAb, Inc. (OABI)

Gyre Therapeutics, Inc. and OmniAb, Inc. are both Biotechnology companies. Gyre Therapeutics, Inc. and OmniAb, Inc. are of similar size ($687.7M and $678.6M). OmniAb, Inc. grew revenue faster over the last twelve months: 67.0% against 10.7%. Gyre Therapeutics, Inc. has the higher net margin (−13.7% vs −115.1%) and the higher return on invested capital (−8.51% vs −14.5%). Across the 16 metrics below, Gyre Therapeutics, Inc. leads on 11 and OmniAb, Inc. on 5.

Valuation

Metric GYRE OABI Biotechnology median
P/E n/m n/m 8.50
P/S 5.26 15.37 9.71
P/B 4.29 2.27 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 4.66 14.02 9.21
Earnings yield (3.29%) (7.84%) (33.15%)
Free cash flow yield (1.16%) (3.07%) (25.50%)

Profitability

Metric GYRE OABI Biotechnology median
Gross margin 94.15% 98.28% 65.16%
Operating margin (10.53%) (125.78%) 0.00%
Net margin (13.73%) (115.12%) 0.00%
Free cash flow margin (6.12%) (47.17%) 0.00%
Return on equity (11.75%) (16.95%) (56.36%)
Return on assets (9.08%) (15.11%) (48.04%)
Return on invested capital (8.51%) (14.52%) 0.00%

Growth

Metric GYRE OABI Biotechnology median
Revenue growth (TTM) 10.72% 67.01% 6.02%
EPS growth (last fiscal year) (60.00%) 6.56% 30.26%
Revenue growth, 5-year CAGR 40.96% — 9.41%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric GYRE OABI Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 4.26 4.80 4.72
Net debt to EBITDA (3.74) 1.12 0.96

Dividend

Metric GYRE OABI Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric GYRE OABI Biotechnology median
Market cap 678.62m 687.70m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack